Today, Getinge announces its support of the American Heart Association initiative to build a Cardiogenic Shock Registry. This unparalleled initiative will enable a wide range of cardiogenic shock research, based on patient data from hospitals across the US, and lead to opportunities to promote best practices and improve clinical outcomes.
Historically, data related to cardiogenic shock has been limited, inconsistent, and challenging to interpret. If not treated quickly, cardiogenic shock can lead to organ failure and death. Even when treated timely and at specialized centers, the rate of survival after cardiogenic shock remains dismal. The American Heart Association initiative to collect evidence in cardiogenic shock patients across US hospitals and create a Cardiogenic Shock Registry in collaboration with academic clinicians, researchers, federal agencies and industry experts, is unparalleled.
“Cardiogenic shock is a life-threatening condition where the heart suddenly can’t pump enough blood to meet the body’s demands, and is often caused by a severe heart attack or advanced heart failure as a complication of a variety of heart conditions. It is a common cause of mortality and the management of these patients remains challenging despite advancement in therapeutic options,” says Dr. Pierluca Lombardi, Corporate Medical Officer at Getinge.
Getinge has a long history of providing products and solutions within the cardiovascular space, making the support to the American Heart Association in establishing its Cardiogenic Shock Registry very natural.
“The American Heart Association came up with a brilliant way of fostering collaboration among experts, and we want to support that. The data collected will provide high-quality evidence and important best practice treatments for health care stakeholders”, says Dr. Lombardi. “I’m convinced it will be a game changer for both clinicians and patients, and a step towards more equal and sustainable care.”